losartan has been researched along with olmesartan medoxomil in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (56.52) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
| Ball, KJ; Stumpe, KO; Williams, PA | 1 |
| Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Minamino, T; Node, K; Ogai, A; Ogita, H; Sakata, Y; Sanada, S; Takashima, S; Yamada, J | 1 |
| Terra, SG | 1 |
| Dominiak, P; Häuser, W | 1 |
| Averill, DB; Brosnihan, KB; Ferrario, CM; Gallagher, PE; Ishiyama, Y; Tallant, EA | 1 |
| Carey, RM | 1 |
| Arakawa, K | 1 |
| Stumpe, KO | 1 |
| Dubiel, R; Jones, M; Smith, DH | 1 |
| Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR | 1 |
| Giles, TD; Oparil, S; Silfani, TN; Walker, JF; Wang, A | 1 |
| Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J | 1 |
| Chavanu, KJ; Dubiel, R; Flack, JM; Li, W; Punzi, HA; Stoakes, KA; Weir, MR | 1 |
| Circelli, M; Cremonesi, G; Fogari, R; Mugellini, A | 1 |
| Khan, BV | 1 |
| Chavanu, KJ; Flack, JM; Graff, A; Li, W | 1 |
| Chavanu, KJ; Lewin, A; Li, W; Punzi, HA | 1 |
| Asai, S; Kanou, N; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y | 1 |
5 review(s) available for losartan and olmesartan medoxomil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Development of combined drugs (ARB and diuretics)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Diuretics; Drug Combinations; Drug Design; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Kidney Tubules, Proximal; Losartan; Olmesartan Medoxomil; Practice Guidelines as Topic; Renin-Angiotensin System; Sodium; Telmisartan; Tetrazoles | 2004 |
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Indans; Irbesartan; Losartan; Nitrobenzenes; Obesity; Olmesartan Medoxomil; Piperazines; Ramipril; Tetrazoles; Valine; Valsartan | 2011 |
The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.
Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Losartan; Olmesartan Medoxomil; Reproducibility of Results; Tetrazoles | 2011 |
6 trial(s) available for losartan and olmesartan medoxomil
| Article | Year |
|---|---|
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Monitoring, Physiologic; Olmesartan Medoxomil; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2005 |
[Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; China; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2006 |
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Single-Blind Method; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2011 |
Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension.
Topics: Analysis of Variance; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Least-Squares Analysis; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Placebos; Prospective Studies; Tetrazoles; Treatment Outcome | 2012 |
Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Ethnicity; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2012 |
12 other study(ies) available for losartan and olmesartan medoxomil
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Captopril; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypertension; Imidazoles; Losartan; Multicenter Studies as Topic; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles | 2001 |
Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Cardiomegaly; Coronary Vessels; Enalapril; Enzyme Inhibitors; Heart Rate; Heart Ventricles; Imidazoles; Losartan; Male; Mitogen-Activated Protein Kinases; Myocardium; Neutrophil Infiltration; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Olmesartan Medoxomil; Organ Size; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Ribosomal Protein S6 Kinases; Tetrazoles; Thiazepines | 2001 |
[Changed guidelines of the German High Blood Pressure League. AT(1) blocker in the first league now].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Losartan; Olmesartan Medoxomil; Tetrazoles; Time Factors | 2002 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diuretics; Dizziness; Drug Combinations; Drug Interactions; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
[Fast-acting sartan. High blood pressure therapy without long waiting time].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Rats; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan | 2003 |
Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; Cardiomyopathy, Hypertrophic; Coronary Vessels; Disease Models, Animal; Enzyme Induction; Imidazoles; Ligation; Losartan; Male; Myocardial Infarction; Myocardium; Olmesartan Medoxomil; Peptide Fragments; Peptidyl-Dipeptidase A; Pyridines; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Ventricular Remodeling | 2004 |
Angiotensin type-1 receptor blockade increases ACE 2 expression in the heart.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; Down-Regulation; Enzyme Induction; Heart; Humans; Imidazoles; Losartan; Mice; Myocardial Infarction; Myocardium; Olmesartan Medoxomil; Peptide Fragments; Peptidyl-Dipeptidase A; Pyridines; Rats; Rats, Inbred Lew; Tetrazoles | 2004 |
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzimidazoles; Biological Transport; Biphenyl Compounds; Digoxin; Fluoresceins; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Membrane Transport Proteins; Mice; Multidrug Resistance-Associated Protein 2; Olmesartan Medoxomil; Tetrazoles; Thiophenes | 2010 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Logistic Models; Losartan; Male; Middle Aged; Multivariate Analysis; Olmesartan Medoxomil; Retrospective Studies; Telmisartan; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan | 2013 |